Bardia, Aditya <br/><br/>
EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer.  [electronic resource] 

 -  Future oncology (London, England)  Oct 2019 
 - 3209-3218 p.  digital 
<br/><br/> Publication Type: Clinical Trial Protocol; Journal Article 
<br/><br/><label>ISSN: </label>1744-8301 
<br/><br/><label>Standard No.: </label>10.2217/fon-2019-0370  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Female<br/>Humans<br/>Middle Aged<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Estrogen Receptor alpha--metabolism<br/>Follow-Up Studies<br/>Fulvestrant--administration & dosage<br/>International Agencies<br/>Prognosis<br/>Prospective Studies<br/>Survival Rate<br/>Tetrahydronaphthalenes--administration & dosage<br/>Randomized Controlled Trials as Topic<br/>Multicenter Studies as Topic